FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...
New targeted therapies reshape biliary tract cancer care, highlighting FGFR2/IDH1, HER2 and KRAS options plus smarter ...
Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...
Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists. Lung cancer treatment has undergone a remarkable transformation ...
Revised trial procedures add intensified hematologic and cardiac monitoring to mitigate toxicities consistent with dual ...
The pivotal MajesTEC-3 trial led to FDA approval of teclistamab-daratumumab for relapsed/refractory multiple myeloma after at ...
Dr. Costa addresses community-based versus academic center care debates for complex patients requiring multiple therapy lines ...
During a live event, Patrick Hagen, MD, considered the evidence for using teclistamab plus daratumumab in a patient with myeloma relapse after quadruplet induction and transplant.
NCCN now recognizes image-only, mammogram-derived AI as a primary risk tool, shifting risk stratification from ...
At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...
In an interview with Targeted Oncology, Naomi Haas, MD, discusses the evolving landscape of adjuvant and neoadjuvant immune ...
Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results